Envista Holdings Corp Q3 FY2024 earnings call

• Paul Keel started by noting Q3 results came in as expected, reaffirming full-year guidance. He discussed market trends, with the overall market flat, implant segment up slightly, orthodontic segment flat to slightly positive, diagnostics soft but North America a bright spot, and consumables flat to slightly positive. Eric Hammes then detailed revenue dynamics, margin bridge, free cash flow, and working capital management. Key operational highlights included investments in growth, new offerings in diagnostics, and rebuilding the execution foundation through initiatives like relaunching EBS.

Specialty Products and Technology

• Core revenue declined 5.2% versus prior year. Orthodontic business declined low double digits in Q3 due to Spark revenue deferral impact; without this, orthodontic revenues grew mid-single digits. Spark saw slowing case growth but continued to take share with active doctors growing double digits. Implant growth was flat versus prior year, with North America gap closing helped by value implants growth and improving Nobel trend.

Equipment and Consumables

• Core sales decreased by 5.6% versus prior year. Diagnostics declined mid-single digit, with North America being a bright spot growing low single digit. Consumables sellout was flat to slightly positive, with North America low single digit growth, Europe mid-single digit, and Russia double digits.

• Reconfirmed full-year guidance of negative 1% to negative 4% reported core growth and 10% to 12% adjusted EBITDA margins. Expect Q4 to return to growth on a reported basis. The Spark revenue deferral impact will be meaningfully lower in Q4 and turn to a tailwind in 2025.

• Market volatility, including geopolitical and macroeconomic uncertainties in China. Impact of hurricanes on customers in regions like Florida. Forward-looking statements subject to risks and uncertainties where actual results may differ materially from projections.

Q: Elizabeth Anderson asked about whether Q3 performance was due to market improvement or execution, and guidance.

A: Paul Keel said market was not a contributor to above-expectations performance as dental market growth remained slow, but Envista was beginning to resharpen execution by shoring up foundation. Eric Hammes commented on guidance being a balance of motivating but achievable bar and providing underlying performance depth.

Q: Jeff Johnson asked about Spark deferrals, including catch-up provisions, deferral rate, and revenue impact on margins.

A: Paul Keel explained no change in deferral rate, Q3 Spark deferral impact was due to initial recognition and timing of deferred revenue, and the deferred revenue when it comes back will flow through gross margin and operating profit dollars.

Q: Erin Wright asked about growth investments, China market.

A: Paul Keel said growth investments are high return, focusing on rebuilding execution rhythm, and China is a long-term attractive market but near term is turbulent due to geopolitical and macroeconomic factors.

Q: Jon Block asked about implant segment performance, investments, and Spark margin.

A: Paul Keel discussed geographic performance of implants, ongoing investments in growth, and Spark having six straight quarters of gross margin improvement with confidence in continued margin improvement leading to operating margin positive in 2025.

Q: Michael Cherney asked about investments in product portfolio.

A: Paul Keel said they think about accelerating growth and improving productivity in parallel, with investments to restart growth exceeding incremental gross margin dollars this year but expecting investments to be funded by operating performance as growth accelerates.

Q: Kevin Caliendo asked about adjusted EBITDA bridge, 4Q guidance, and product portfolio rationalization.

A: Paul Keel discussed 4Q factors like reduced Spark deferral impact, seasonality, and investment levels, and said the company is happy with current product portfolio in short term but constantly refining it in medium and longer term.

Q: Brandon Vazquez asked about implants investments and performance.

A: Paul Keel discussed investments in implants across commercial, clinical, and new product development horizons, with value implants in North America growing mid-single digits and progress in both value and premium segments.

Q: Vivek Chopra asked about dental market recovery and impact of hurricanes.

A: Paul Keel said global dental market normalized growth is 3-5%, and impact of hurricanes on customers in Florida was noted but not a material effect on Envista.